CORDENPHARMA BOULDER (CO, US)
Highly Potent API Video
CordenPharma 15 Year Anniversary
Core Capabilities
- >> Development & manufacturing of highly potent, cytotoxic & cytostatic APIs
- >> Development to commercial quantities
- >> Highly potent chromatography expertise
COMPLIANCE
- >> Long history of successful US FDA inspections
- >> PMDA inspected with zero critical observations
- >> Inspected by TGA
- >> Inspected by MHRA
Related Products & Platforms
Drug Products
Technology Platforms
Facility Legacy
CordenPharma Boulder is a world leader in the development and manufacturing of highly potent cytotoxic and cytostatic products, bringing expertise in process development, scale-up and cGMP manufacturing for highly potent APIs as well as experience in handling compounds below 10ng/m3 OEL.
HISTORY
- >> 1991: Site founded as NaPro Biotherapeutics
- >> 2003: Mayne Pharma acquired the facility
- >> 2007: Became a member of Hospira due to the acquisition of Mayne
- >> 2015: Pfizer acquired Hospira
- >> 2017: Acquired by ICIG to become Corden Pharma Boulder
- >> 2022 Astorg acquires CordenPharma from ICIG
Managing Director
Craig Dixon
Corden Pharma Boulder
4876 Sterling Drive
Boulder 80301
Phone: +1 303 442-1926 Ext. 6623
Fax: +1 303 938-1255